<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173949</url>
  </required_header>
  <id_info>
    <org_study_id>EMC169-15</org_study_id>
    <nct_id>NCT04173949</nct_id>
  </id_info>
  <brief_title>Explorative Study for Treating Persistent Developmental Stuttering With Ramipril</brief_title>
  <official_title>Explorative Study for Treating Persistent Developmental Stuttering With Ramipril</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HaEmek Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HaEmek Medical Center, Israel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Persistent developmental stuttering (PDS) is diagnosed when developmental stuttering persists&#xD;
      beyond adolescence. Most stutterers experience vast improvement in stuttering during&#xD;
      childhood and it generally disappears within five years. A minority of stutterers continue&#xD;
      stuttering over age 18, often accompanied by social and personal difficulties.&#xD;
&#xD;
      Following a report of a 75 year old woman, with severe Persistent developmental stuttering ,&#xD;
      who experienced significant improvement in her stuttering since treated by Ramipril for&#xD;
      hypertension, we scrutinized the literature, and discovered that there is a physiological&#xD;
      basis for this surprising reaction. Ace inhibitors, such as Ramipril, might in fact be&#xD;
      successful for treating Persistent developmental stuttering .&#xD;
&#xD;
      In theory, it seems that ACE inhibitors, such as Ramipril could improve stuttering by&#xD;
      reducing striatum dopamine levels.&#xD;
&#xD;
        1. Stuttering is associated with high striatum dopamine levels&#xD;
&#xD;
        2. Angiotensin receptors are present in the striatum&#xD;
&#xD;
        3. Angiotensin causes elevated striatum dopamine levels&#xD;
&#xD;
        4. ACE inhibitors penetrate the blood brain barrier and reduce brain angiotensin II levels.&#xD;
&#xD;
      Methods The study will begin as a pilot study in which 10 stuttering patients will be&#xD;
      recruited for 12 weeks on open label Ramipril 1.25mg/d.&#xD;
&#xD;
      If there is improvement in at least 2 of the stuttering patients, we will continue to the&#xD;
      main study.&#xD;
&#xD;
      Efficacy Evaluation:&#xD;
&#xD;
        1. The MINI Neuropsychiatric interview will be used to rule out major neuropsychiatric&#xD;
           conditions&#xD;
&#xD;
        2. Stuttering evaluation&#xD;
&#xD;
             1. Stuttering Severity instrument Version 4 (SSI-4) (Riley 2009)&#xD;
&#xD;
             2. SLD :Percentage of stuttered syllables (Yairi 2015)&#xD;
&#xD;
             3. The Subjective Screening of Stuttering (SSS)&#xD;
&#xD;
             4. Speech Situation Checklist (Brutten 1975,1981)&#xD;
&#xD;
        3. Leibowitz Social Anxiety Scale (Leibowitz 1987)&#xD;
&#xD;
      The efficacy evaluation will be performed by speech therapists. All evaluations will be will&#xD;
      be recorded on video&#xD;
&#xD;
      Safety evaluation:&#xD;
&#xD;
        1. Blood pressure: The average of three consecutive measures. Blood pressure will be&#xD;
           measure in both arms on the first meeting, and thereafter on the arm with the highest&#xD;
           measurements.&#xD;
&#xD;
        2. Orthostatic hypotension will be defined as a drop of 20mmHg systolic or 10mmHg&#xD;
           diastolic, one and three minutes after standing from sitting position.&#xD;
&#xD;
        3. Creatinine clearance will be calculated by the MDRD method (Levy 2006) GFR, in mL/min&#xD;
           per 1.73 m2 = 186.3 x SCr (exp[-1.154]) x Age (exp[-0.203]) x (0.742 if female) x (1.21&#xD;
           if black)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>The study will begin as a pilot study in which 10 stuttering patients will be recruited for 12 weeks on open label Ramipril 2.5mg.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changed in stuttered syllables</measure>
    <time_frame>4 month</time_frame>
    <description>The difference in stuttering measures with and without treatment will be determined.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Persistent Developmental Stuttering</condition>
  <arm_group>
    <arm_group_label>Ramipril 2.5 MG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramipril 2.5 MG orall, daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril 2.5 MG</intervention_name>
    <description>3 month of treatment with daily Ramipril 2.5 MG</description>
    <arm_group_label>Ramipril 2.5 MG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or above&#xD;
&#xD;
          -  Developmental stuttering of 10 points severity at least (SSI-4)&#xD;
&#xD;
          -  Agree not to have any speech or emotional therapy during the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic blood pressure &lt; 110mmHg&#xD;
&#xD;
          -  Estimated creatinine clearance &lt; 50ml/min&#xD;
&#xD;
          -  Baseline potassium &gt; 5meq/ml&#xD;
&#xD;
          -  Any sign of psychopathology by the MINI international neuropsychiatric interview&#xD;
&#xD;
          -  Any psychotropic medications or substances in the past month&#xD;
&#xD;
          -  History of angioedema or cough with any ACE inhibitor&#xD;
&#xD;
          -  Aliskerin use in diabetes patients&#xD;
&#xD;
          -  Current medication include ACE inhibitors or ARBS&#xD;
&#xD;
          -  Pregnancy, or pregnancy plans during the study&#xD;
&#xD;
          -  Less than 3% stuttered syllables&#xD;
&#xD;
          -  Subjects with cluttering-stuttering when the cluttering is prominent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Haemek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>gilat ron avraham, mph</last_name>
      <phone>972-4-6495590</phone>
      <email>gilat_av@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Lee H Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asaf Harophe</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Goldstein</last_name>
      <phone>972-4-6495590</phone>
      <email>goldstein_le@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stuttering</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

